NASDAQ:ABOS Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free ABOS Stock Alerts $3.13 -0.02 (-0.63%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$3.12▼$3.2650-Day Range$3.09▼$4.6452-Week Range$1.81▼$11.31Volume479,013 shsAverage Volume381,948 shsMarket Capitalization$188.05 millionP/E RatioN/ADividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Acumen Pharmaceuticals alerts: Email Address Acumen Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside291.4% Upside$12.25 Price TargetShort InterestHealthy2.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.22) to ($1.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.53 out of 5 starsMedical Sector443rd out of 909 stocksBiological Products, Except Diagnostic Industry67th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingAcumen Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcumen Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.88% of the float of Acumen Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcumen Pharmaceuticals has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acumen Pharmaceuticals has recently increased by 21.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcumen Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcumen Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABOS. Previous Next 3.1 News and Social Media Coverage News SentimentAcumen Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Acumen Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest6 people have searched for ABOS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows2 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Acumen Pharmaceuticals is held by insiders.Percentage Held by Institutions71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.22) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acumen Pharmaceuticals is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acumen Pharmaceuticals is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcumen Pharmaceuticals has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Acumen Pharmaceuticals Stock (NASDAQ:ABOS)Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Read More ABOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABOS Stock News HeadlinesApril 18, 2024 | markets.businessinsider.comThese 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say AnalystsApril 17, 2024 | msn.comAcumen Pharmaceuticals (ABOS) Price Target Increased by 6.67% to 13.06April 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 16, 2024 | globenewswire.comAcumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual MeetingApril 13, 2024 | americanbankingnews.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Up 21.6% in MarchApril 4, 2024 | finance.yahoo.comAcumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s TreatmentApril 4, 2024 | markets.businessinsider.comAcumen Pharma Partners Lonza To Advance Sabirnetug For Alzheimer's Disease TreatmentApril 4, 2024 | finance.yahoo.comAcumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s DiseaseApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 4, 2024 | globenewswire.comAcumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's DiseaseApril 4, 2024 | msn.comSames Auto Group partners with Driscoll Children’s HospitalMarch 27, 2024 | msn.comAcumen Pharmaceuticals files for $200M mixed shelf offeringMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acumen Pharmaceuticals on Promising Alzheimer’s Drug Trial OutcomesMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Alzheimer’s Treatment Development and Attractive ValuationMarch 27, 2024 | finance.yahoo.comQ4 2023 Acumen Pharmaceuticals Inc Earnings CallMarch 27, 2024 | finance.yahoo.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | globenewswire.comAcumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business HighlightsMarch 19, 2024 | globenewswire.comAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024March 12, 2024 | globenewswire.comAcumen Pharmaceuticals to Participate in the Stifel 2024 CNS DaysMarch 8, 2024 | finance.yahoo.comAcumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual MeetingFebruary 24, 2024 | finance.yahoo.comInstitutional investors own a significant stake of 42% in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)February 21, 2024 | finance.yahoo.comAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual MeetingFebruary 21, 2024 | globenewswire.comAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual MeetingFebruary 17, 2024 | finance.yahoo.comABOS Mar 2024 2.500 putFebruary 7, 2024 | finance.yahoo.comBuy Alert: 3 Healthcare Stocks Sitting in the Sweet SpotFebruary 1, 2024 | finance.yahoo.com3 Healthcare Stocks to Buy as the Sector Benefits from the Aging BoomFebruary 1, 2024 | finance.yahoo.comAcumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development OfficerSee More Headlines Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today4/22/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ABOS CUSIPN/A CIK1576885 Webwww.acumenpharm.com Phone434-297-1000FaxN/AEmployees39Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$15.00 Low Stock Price Target$8.00 Potential Upside/Downside+291.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.40% Return on Assets-21.78% Debt Debt-to-Equity Ratio0.11 Current Ratio19.01 Quick Ratio19.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.61 per share Price / Book0.68Miscellaneous Outstanding Shares60,080,000Free Float55,574,000Market Cap$188.05 million OptionableOptionable Beta0.08 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Daniel J. O'Connell M.B.A. (Age 53)CEO & Director Comp: $901.2kMr. Matt ZugaCFO & Chief Business OfficerMr. Derek M. Meisner Esq. (Age 53)J.D., Chief Legal Officer & Corporate Secretary Comp: $240.17kDr. James Doherty Ph.D. (Age 56)President & Chief Development Officer Dr. Grant A. Krafft Ph.D.Co-FounderDr. Caleb E. Finch Ph.D.Co-FounderDr. William L. Klein Ph.D.Co-FounderMr. Russell Barton M.S. (Age 65)Chief Operating Officer Comp: $223.68kMs. Kelly CarranzaVice President, Finance & Accounting and Corporate ControllerMs. Alex Braun M.B.A.VP & Head of Investor RelationsMore ExecutivesKey CompetitorsInnate PharmaNASDAQ:IPHAElevation OncologyNASDAQ:ELEVOptheaNASDAQ:OPTCardiff OncologyNASDAQ:CRDFCompass TherapeuticsNASDAQ:CMPXView All CompetitorsInsiders & InstitutionsChicago Partners Investment Group LLCBought 4,736 shares on 2/23/2024Ownership: 0.032%Parkman Healthcare Partners LLCBought 103,683 shares on 2/15/2024Ownership: 1.042%Franklin Resources Inc.Bought 520,044 shares on 2/9/2024Ownership: 5.800%Jump Financial LLCBought 69,100 shares on 2/7/2024Ownership: 0.178%Simplex Trading LLCSold 7,300 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ABOS Stock Analysis - Frequently Asked Questions Should I buy or sell Acumen Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABOS shares. View ABOS analyst ratings or view top-rated stocks. What is Acumen Pharmaceuticals' stock price target for 2024? 5 analysts have issued 1 year price objectives for Acumen Pharmaceuticals' stock. Their ABOS share price targets range from $8.00 to $15.00. On average, they expect the company's share price to reach $12.25 in the next year. This suggests a possible upside of 291.4% from the stock's current price. View analysts price targets for ABOS or view top-rated stocks among Wall Street analysts. How have ABOS shares performed in 2024? Acumen Pharmaceuticals' stock was trading at $3.84 at the start of the year. Since then, ABOS shares have decreased by 18.5% and is now trading at $3.13. View the best growth stocks for 2024 here. Are investors shorting Acumen Pharmaceuticals? Acumen Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,240,000 shares, an increase of 21.6% from the March 15th total of 1,020,000 shares. Based on an average trading volume of 369,100 shares, the short-interest ratio is currently 3.4 days. Approximately 2.9% of the company's shares are sold short. View Acumen Pharmaceuticals' Short Interest. When is Acumen Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ABOS earnings forecast. How were Acumen Pharmaceuticals' earnings last quarter? Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) released its earnings results on Tuesday, March, 26th. The company reported ($0.29) earnings per share for the quarter, hitting the consensus estimate of ($0.29). What ETF holds Acumen Pharmaceuticals' stock? iShares Neuroscience and Healthcare ETF holds 2,998 shares of ABOS stock, representing 0.28% of its portfolio. When did Acumen Pharmaceuticals IPO? Acumen Pharmaceuticals (ABOS) raised $125 million in an initial public offering (IPO) on Thursday, July 1st 2021. The company issued 8,333,333 shares at a price of $14.00-$16.00 per share. How do I buy shares of Acumen Pharmaceuticals? Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABOS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
